Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts

Laurence Goffin1, Queralt Seguin-Estévez2, Montserrat Alvarez1, Walter Reith2 and Carlo Chizzolini*1

Abstract

Introduction: Extracellular matrix (ECM) turnover is controlled by the synthetic rate of matrix proteins, including type I collagen, and their enzymatic degradation by matrix metalloproteinases (MMPs). Fibrosis is characterized by an unbalanced accumulation of ECM leading to organ dysfunction as observed in systemic sclerosis. We previously reported that proteasome inhibition (PI) in vitro decreases type I collagen and enhances MMP-1 production by human fibroblasts, thus favoring an antifibrotic fibroblast phenotype. These effects were dominant over the pro-fibrotic phenotype induced by transforming growth factor (TGF)-β. Here we investigate the molecular events responsible for the anti-fibrotic phenotype induced in fibroblasts by the proteasome inhibitor bortezomib.

Methods: The steady-state mRNA levels of COL1A1, COL1A2, TIMP-1, MMP-1, and MMP-2 were assessed by quantitative PCR in human dermal fibroblasts cultured in the presence of TGF-β, bortezomib, or both. Transient fibroblast transfection was performed with wild-type and mutated COL1A1 and MMP-1 promoters. Chromatin immunoprecipitation, electrophoretic mobility shift assay (EMSA), and DNA pull-down assays were used to assess the binding of c-Jun, SP1, AP2, and Smad2 transcription factors. Immunoblotting and immunofluorescent microscopy were performed for identifying phosphorylated transcription factors and their cellular localization.

Results: Bortezomib decreased the steady-state mRNA levels of COL1A1 and COL1A2, and abrogated SP1 binding to the promoter of COL1A2 in both untreated and TGF-β-activated fibroblasts. Reduced COL1A2 expression was not due to altered TGF-β-induced Smad2 phosphorylation, nuclear translocation, or binding to the COL1A2 promoter. In contrast to collagen, bortezomib specifically increased the steady-state mRNA levels of MMP-1 and enhanced the binding of c-Jun to the promoter of MMP-1. Furthermore, disruption of the proximal AP-1-binding site in the promoter of MMP-1 severely impaired MMP-1 transcription in response to bortezomib.

Conclusions: By altering the binding of at least two transcription factors, c-Jun and SP1, proteasome inhibition results in increased production of MMP-1 and decreased synthesis of type I collagen in human dermal fibroblasts. Thus, the antifibrotic phenotype observed in fibroblasts submitted to proteasome inhibition results from profound modifications in the binding of key transcription factors. This provides a novel rationale for assessing the potential of drugs targeting the proteasome for their anti-fibrotic properties.

Introduction
The extracellular matrix (ECM) provides a controlled environment for cellular differentiation and tissue development, thereby participating in the maintenance of organ morphology and function. ECM integrity results from a continuous and tightly regulated deposition and degradation of its components. Type I collagen is among the most abundant ECM proteins and its excessive dermal deposition is one of the key features of systemic sclerosis (SSc) (scleroderma), a prototypic fibrotic condition...
Type I collagen forms a characteristic triple-helix structure composed of two alpha1 subunits and one alpha2 subunit, encoded by the collagen 1A1 (COL1A1) and COL1A2 genes, of which the coordinated transcription rates ensure a 2:1 ratio [4].

Among various soluble molecules inducing the production of type I collagen, the most extensively studied is transforming growth factor-beta (TGF-β) [5,6]. TGF-β-responsive elements have been mapped in the -378/-183 region of the mouse and human COL1A2 promoter [7,8]. TGF-β-mediated increase in the production of type I collagen results from increased binding of transcription factors to three GC-rich SP1 sites (in the -303/-271 region) and one activation protein-1 (AP-1) site (-265/-241) within the COL1A2 promoter [9]. SP1 binding is essential since blocking SP1 recruitment by point mutations in the DNA consensus sequence leads to inhibition of type I collagen synthesis, and overexpression of SP1 stimulates both basal and TGF-β-mediated COL1A2 transcription [8]. Furthermore, Smad2/3 signaling molecules induced by TGF-β [10] bind to the SP1 consensus sequence in the COL1A2 promoter region. Smad2/3 interacts also with the transcriptional co-activators p300/CREB-binding protein (CBP), which enhance both basal and TGF-β-induced COL1A2 promoter activity [11].

Matrix metalloproteinases (MMPs) play a major role in ECM degradation. They are regulated at the transcriptional level and undergo post-transcriptional maturation and their catalytic activity is inhibited by tissue inhibitors of MMP (TIMPs) [12,13]. MMP-1 or interstitial collagenase unwinds native type I collagen and initiates its degradation, whereas MMP-2 and MMP-9 are two gelatinases, which efficiently digest degraded collagen. Interestingly, these MMPs are not co-ordinately regulated. Tumor necrosis factor-alpha (TNF-α) enhances MMP-1 [14] and MMP-9 [15] expression, whereas TGF-β enhances MMP-2 [16] and MMP-9 [17] synthesis but decreases MMP-1 production [18].

The proteasome is a barrel-shaped, multi-catalytic protease complex present in the cytosol and in the nuclei and triggers degradation of multi-ubiquitinated proteins [19]. It maintains cell homeostasis by promoting clearance of damaged or improperly folded proteins and degrades key components involved in the cell cycle and cell signaling [20]. We recently reported that proteasome inhibition (PI) profoundly modifies the phenotype of human dermal fibroblasts by reducing type I collagen synthesis and increasing MMP-1 production [21]. This effect was dominant on the pro-fibrotic activity of TGF-β and observed in normal as well as SSc fibroblasts. Furthermore, PI induced the phosphorylation, accumulation, and nuclear translocation of c-Jun. These in vitro characteristics are consistent with the anti-fibrotic activity exerted by PI in many, but not all, in vivo models of fibrosis [22-27].

In the present study, we aimed at dissecting the molecular mechanisms involved in the anti-fibrotic activity of PI on human dermal fibroblasts. We inhibited the proteasome with bortezomib, a highly specific and potent PI used in humans as a therapeutic agent for multiple myeloma [28-30]. We provide evidence that the anti-fibrotic property of PI results from both the induction of MMP-1 expression via proximal AP-1 sites and the repression of COL1A2 transcription via SP1 sites.

**Materials and methods**

**Cell culture**

A primary human fibroblast cell line was established from skin punch biopsies of a healthy donor, as described previously [21]. Permission to perform this investigation was granted by the ethics committee of our institution. Informed consent was obtained in accordance with the Declaration of Helsinki. Fibroblasts were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen Corporation, Carlsbad, CA, USA), supplemented with 10% fetal calf serum (FCS) (Sigma-Aldrich, St. Louis, MO, USA), 2 mM glutamine (Invitrogen Corporation), non-essential amino acids (Invitrogen Corporation), 50 U/mL penicillin, and 50 μg/mL streptomycin (Invitrogen Corporation) and grown in 5% CO₂ at 37°C. Fibroblasts used at passages 5 to 14 were grown up to 80% confluence, starved overnight in medium containing 1% FCS, and then cultured in the presence of TGF-β (5 ng/mL), bortezomib (1 μM), or TNF-α (10 ng/mL) for the desired periods of time.

**Reagents and antibodies**

Bortezomib (PS-341, Velcade) was from Millennium Pharmaceuticals (Cambridge, MA, USA). TGF-β and TNF-α were from R&D Systems, Inc. (Minneapolis, MN, USA). Immunolabeling and immunoprecipitation were performed using anti-type I collagen (SouthernBiotech, Birmingham, AL, USA), anti-MMP-1 (Chemicon International Inc., Temecula, CA, USA), anti-phospho-c-Jun, anti-phospho-Smad2, and anti-c-Jun (Cell Signaling Technology, Inc., Beverly, MA, USA), anti-AP2, anti-SPI, anti-p300, anti-Ets1, and anti-TFIIEα (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-Smad2/3 (Upstate, now part of Millpore Corporation, Billerica, MA, USA), anti-β-tubulin (Sigma-Aldrich) primary antibodies, and anti-goat (The Binding Site, Birmingham, UK) or anti-rabbit or anti-mouse (DakoCytomation, Baar, Switzerland) IgG antibodies coupled to horseradish peroxidase. For DNA pull-down assays, streptavidin agarose beads were from Pierce Biotechnology (Rockford, IL, USA).
Quantitative reverse transcription-polymerase chain reaction

Total RNA was extracted with TRizol reagent (Invitrogen Corporation), and 1 μg was reverse-transcribed using random primers and Superscript II (Invitrogen Corporation). Real-time polymerase chain reaction (PCR) was performed with an ABI PRISM SDS 7900 instrument (Applied Biosystems, Foster City, CA, USA) using TaqMan probes (Applied Biosystems) and with an ABI PRISM SDS 7700 instrument using an SYBR-Green based kit for quantitative PCR (Eurogentec, Liege, Belgium). For each sample, gene expression was normalized using human elongation factor 1 mRNA (HsEEF1A1). Primers used for PCR are listed in Table 1.

Immunoblotting and enzyme-linked immunosorbent assay

Type I collagen, MMP-1, MMP-2, and TIMP-1 proteins were quantified in the supernatants of fibroblasts submitted to various culture conditions for 48 hours. Type I collagen and MMP-1 were quantified by immunoblotting in culture supernatants concentrated to one tenth of their original volume using Vivaspin 6-mL concentrators (Sartorius AG, Goettingen, Germany). Total protein (20 μg) was resolved by SDS-PAGE, transferred onto nitrocellulose membranes (Hybond; Amersham Biosciences, now part of GE Healthcare, Little Chalfont, UK), and immunoblotted with specific antibodies [21]. Signals were revealed according to enhanced chemiluminescence (ECL) protocols (GE Healthcare) and quantified by phosphor imaging. TIMP-1 and MMP-2 were quantified by enzyme-linked immunosorbent assay in accordance with the instructions of the manufacturer (R&D Systems, Inc.).

Transient cell transfection and reporter gene assays

Plasmids carrying the Renilla luciferase gene under control of the constitutive Herpes simplex virus thymidine kinase (TK) promoter (pGL4.74) and plasmids carrying the firefly luciferase gene under control of the constitutive SV40 promoter (pLG4.13) were purchased from Promega Corporation (Madison, WI, USA). The pLG2-derived plasmids, containing the wild-type (TGACTCA) or variant (TTACGTCA) AP-1 site situated at -72 of the MMP-1 promoter, were kindly provided by Franck Verrecchia (Hôpital Saint-Louis, Paris, France) [31]. The pLG2-derived plasmids containing the wild-type (-311/+114) or deleted (-112/+114) COL1A1 promoter were kindly provided by Philippe Galera (CHU, Caen, France) [32]. A promoter-free plasmid encoding firefly luciferase (pLG4.10) was used as a negative control. The day before transfection, fibroblasts were seeded in six-well plates to reach 80% confluence. Various combinations of plasmid DNA (1 μg total) and 3 μL of transfection reagent (Transfast from Promega Corporation) were added to 1 mL of medium containing 1% FCS and mixed vigorously. The

| Table 1: Oligonucleotide sequences |
|-----------------------------------|
| **Name**                        | **Sequence**                        |
| **Electrophoretic mobility shift assay** |                  |
| MMP-1 AP-1 S                   | CTAGTGATGAGTCAAGCGGATGC              |
| MMP-1 AP-1 AS                   | GATCCGGCTGACTCATTAGCAGC             |
| **Chromatin immunoprecipitation** |                  |
| MMP-1 AP-1 fw                   | CCTCTTGTGCTGTCAAATCT                |
| MMP-1 AP-1 rv                   | TCTGCTTGTGACCACTATTTC               |
| MMP-2 AP2 fw                    | GTGAGAGGGGCGGAGGATAGGG              |
| MMP-2 AP2 rv                    | CTGGAGAGGGGCGGAGGAGGAGG             |
| MMP-9 AP-1 fw                   | GAGAGGAGGAGGTGGTGTAAG               |
| MMP-9 AP-1 rv                   | TTAAGAGGGGCTCCTGGTG                 |
| COL1A1 -200/+100 fw             | CAGAGCTCGAGAGGAGGAGGGA              |
| COL1A1 -200/+100 rv             | AGACTCTTTGTGCTGGGAGGAG              |
| COL1A2 fw2                     | GCCGAGATGCTAGCAACACAG               |
| COL1A2 rv1                     | GGGCTCGCTCTTTAAATTG                 |
| MMP-1 ORF fw                    | TAAGTACTGGGCTTGTCAGG                |
| MMP-1 ORF rv                    | GAGACGATGCTAGATCTTC                 |
| COL1A2 ORF fw                   | GCCCTAAAGGTTTTCAGA                  |
| COL1A2 ORF rv                   | GGGAGACCACATATTTCAC                 |

**Reverse transcription-polymerase chain reaction**

| COL1A1                      | Hs00164004_m1                  |
| COL1A2                      | Hs00164099_m1                  |
| TIMP-1                      | Hs00171558_m1                  |
| MMP-1                       | Hs00233958_m1                  |
| MMP-2                       | Hs00234422_m1                  |
| HsEEF1A1                    | CACCTGAGCATGAAAGCAGCTG         |

**DNA pull-down assay**

| Biotin-MMP-1-S              | GATCAGAGGAGATGTTATAAAGCAGT       |
| Biotin-MMP-1-AS             | CTGACTCATGCTTTATAAACATCTCTC     |
| Biotin-COL1A2-S            | GAAAGGCGGCGGAGGGGCGGAGG        |
| Biotin-COL1A2-AS           | CTCCCGCCTCCGACATCTCCGCC        |

Bold case indicates proximal activation protein-1 (AP-1) site. Underlining indicates transcription binding sites (Ets and AP-1 for matrix metalloproteinase-1 [MMP-1] and SP1 for collagen 1A2 [COL1A2]).
transfection mix contained Renilla luciferase and firefly luciferase plasmids at a ratio of 1 to 10. After 10 minutes at room temperature, the cultures were placed for 1 hour at 37°C, 2 mL of medium containing 10% FCS was added to each well, and the cells were incubated for 48 hours at 37°C. Cell lysis was performed as recommended by the manufacturer (Promega Corporation), and luciferase activities were measured with a Luminometer (Luminoskan Ascent; Thermo LabSystems, now part of Thermo Electron Corporation, Waltham, MA, USA) using the Dual-Luciferase Reporter Assay from Promega Corporation. Firefly luciferase activity was normalized to that of Renilla luciferase. The corrected activities reflect the induction of the tested promoters.

**Chromatin immunoprecipitation**

Chromatin was prepared and immunoprecipitated as previously described [33]. Immunoprecipitated DNA derived from 1 μg of input chromatin DNA and a series of standards containing 0.01 to 10 ng of total input chromatin DNA were analyzed by real-time PCR using primers listed in Table 1. The amount of immunoprecipitated DNA was calculated from a standard curve generated with the input chromatin. Real-time PCR amplifications were repeated in triplicate.

**Nuclear extracts**

Fibroblasts were washed twice with ice-cold phosphate-buffered saline (PBS) and collected with a rubber policeman in 1 mL of PBS containing 1 mM ethylenediaminetetraacetic acid (EDTA). Cells were lysed for 15 minutes on ice in hypotonic buffer (10 mM Hepes pH 7.9; 10 mM KCl; 0.1 mM EDTA; 1 mM dithiothreitol [DTT]; 0.15 vol/vol complete protease inhibitor mix from Roche [Basel, Switzerland]; 0.2 mM phenylmethylsulfonyl fluoride [PMSF]; 100 nM okadaic acid; and 1 mM orthovanadate). The cell lysate was centrifuged at 13,000 rpm for 30 seconds, the supernatants were discarded, and the nuclei were suspended in extraction buffer (20 mM Hepes pH 7.9; 0.4 M NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM DTT; 0.15 vol/vol complete protease inhibitor mix from Roche and 0.2 mM PMSF). Samples were shaken vigorously for 15 minutes at 4°C and centrifuged for 5 minutes at 13,000 rpm, and the supernatants were collected.

**Electrophoretic mobility shift assay**

Complementary oligonucleotides (listed in Table 1) were mixed in a 1:1 molar ratio at 100 pmole/μL, heated for 5 minutes at 95°C, and slowly cooled down to room temperature. Hybridized DNA probes were radiolabeled with γ-32P-ATP in the presence of T4 polynucleotide kinase (Invitrogen Corporation) and purified by chromatography using a Sephadex G-25 spin column (Roche). An aliquot of labeled probe (2 × 10⁴ cpm) was incubated with 5 μg of nuclear extract in binding buffer (nuclear extraction buffer containing 130 ng/μL Poly dIdC, 0.7 mg/mL bovine serum albumin, and 15% glycerol) for 30 minutes at room temperature. Alternatively, the nuclear extract was pre-incubated for 30 minutes at room temperature prior to addition of the probe, with 1 μg of specific antibodies for supershift assays or with a 100-fold excess of cold probe for competition experiments. Protein-DNA complexes were resolved on non-denaturing 4% polyacrylamide gels, and radioactive bands were detected with x-ray films (Kodak BioMax MR film from Sigma-Aldrich).

**DNA pull-down assays**

Complementary biotinylated oligonucleotides (listed in Table 1) were hybridized as described in the EMSA protocol. Annealed biotinylated DNA (1 μg) was incubated with 300 μg of nuclear extract in binding buffer (supplemented with 0.2 mg/mL sheared salmon DNA) for 30 minutes at room temperature, and streptavidin-agarose beads were then added in binding buffer (supplemented with 0.2 mg/mL sheared salmon DNA and 150 mM NaCl) for 3 hours at 4°C. Following three washes in blocking buffer, beads were boiled in Laemmli buffer and eluted proteins were resolved and immunoblotted as described above. Normalization to the total nuclear protein content was performed by Western immunoblotting of the input fractions with anti-TFIIEα antibody.

**Immunofluorescence**

Fibroblasts were seeded on coverslips in six-well plates (5 × 10⁴ cells per well). Cells were washed in PBS, fixed in 4% paraformaldehyde for 20 minutes at room temperature, incubated successively in 1 mM NH₄Cl and 4% Tween, labeled with primary antibody for 1 hour, and then incubated with alexa488-coupled anti-rabbit IgG antibody (Invitrogen Corporation) for 45 minutes at room temperature. Subcellular localization was observed with a fluorescence microscope (Axiovert 200, Carl Zeiss, Gottingen, Germany), and photographs were taken at a magnification of × 40.

**Statistical analysis**

The Student t test was used for statistical analysis. A P value of less than 0.05 was considered significant. To assess the normal distribution of our data, we assessed their skewness and kurtosis, which provided values consistent with normal distribution using the GraphPad Prism version 4.00 (GraphPad Software, Inc., San Diego, CA, USA) for Windows.
Results

Proteasome inhibition abrogates the production of type I collagen induced by TGF-β

We previously reported that PI decreases type I collagen and TIMP-1 production in human dermal fibroblasts [21]. Since type I collagen has a trimeric structure composed of two alpha1 subunits and one alpha2 subunit, we explored whether PI affected the transcription of both the COL1A1 and COL1A2 genes. Bortezomib decreased both COL1A1 (10-fold) and COL1A2 (5-fold) steady-state mRNA levels in a time-dependent manner (Figure 1a, b), as assessed by quantitative PCR. Bortezomib had only modest effects on TIMP-1 mRNA levels (Figure 1c). As expected, TGF-β induced a time-dependent increase in COL1A1 and COL1A2 mRNA levels (Figure 1a-c). Interestingly, the addition of bortezomib 1 hour before TGF-β completely abolished the effect of TGF-β on COL1A1 and COL1A2 (Figure 1a, b). Bortezomib also inhibited, albeit to a lesser extent, TGF-β-induced TIMP-1 transcription (Figure 1c). Consistent with these results, bortezomib strongly inhibited the production of type I collagen and TIMP-1 proteins induced by TGF-β (Figure 1d, e).

TGF-β activates the transcription of COL1A1 and COL1A2 via AP2 and SP1 binding sites, respectively

Transcriptional activation of the COL1A2 gene by TGF-β is controlled mainly by SP1 binding sites in its promoter region [9] (Figure 2a), whereas TGF-β activation of the COL1A1 gene in human dermal fibroblasts remains poorly understood. To partially characterize the requirements for TGF-β responsiveness, we performed luciferase reporter gene assays in human dermal fibroblasts to compare the activity of a full-length COL1A1 promoter with that of a COL1A1 promoter lacking AP2, SP3/SP1, NF-1, and SP1 binding sites [32] (Figure 2a). TGF-β stimulated the full-length COL1A1 promoter, resulting in a threefold increase in the transcriptional activity after 16 hours of incubation. This increase was transient and lost by 24 hours of incubation (Figure 2b). Interestingly, TGF-β had no effect on the activity of the deleted COL1A1 promoter or the constitutive SV40 promoter used as negative control. These experiments indicate that at least one of the transcription factor binding sites (AP2, SP3/SP1, NF-1, SP1) present in the promoter proximal region is required for TGF-β induction of COL1A1 transcription. To assess whether the observed increase in COL1A1 promoter activity induced by TGF-β correlated with an in vivo increase in the binding of specific transcription factors, we performed chromatin immunoprecipitation (ChIP) experiments using SP1- and AP2-specific anti-sera. TGF-β induced a substantial increase in binding of AP2, but not of SP1, to the COL1A1 promoter (Figure 2c). This was distinctly different from the observed increase in binding of SP1, but not of AP2, to the promoter region of COL1A2 in response to TGF-β (Figure 2c). Thus, the coordinated increase in COL1A1 and COL1A2 gene transcription in response to TGF-β is mediated, at least in part, by distinct transcription factors.

Proteasome inhibition abolishes TGF-β-induced SP1 binding to COL1A2 but not of AP2 to COL1A1

We next determined whether PI could affect binding of the identified transcription factors involved in type I collagen gene activation by TGF-β. We quantified binding of AP2 and SP1 to the COL1A1 and COL1A2 promoter regions in fibroblasts cultured in the presence of TGF-β or bortezomib or both. As expected, TGF-β increased binding of AP2 to COL1A1 and SP1 to COL1A2. Conversely, bortezomib potently inhibited the binding of AP2 and SP1 to their respective promoter regions in unstimulated fibroblasts (Figure 2d). Of major interest, bortezomib abolished TGF-β-induced binding of SP1 to COL1A2 (0.6- versus 4.8-fold) but failed to significantly affect TGF-β-induced binding of AP2 to COL1A1 (3.0- versus 3.5-fold) (Figure 2d). Thus, COL1A1 and COL1A2 promoter regions are bound by different transcription factors in response to TGF-β and their binding is affected differently by PI.

Proteasome inhibition does not affect TGF-β-induced Smad2 phosphorylation, nuclear translocation, or binding to the COL1A2 promoter

TGF-β-mediated activation of the COL1A2 gene is triggered by binding of a transcription factor complex comprising SP1, p300, and Smad2/3 to the SP1 sites in its promoter region [9]. We were interested in investigating whether the inhibitory effect of PI on SP1 binding to COL1A1 could be due to its effects on Smad2 signaling. We therefore studied the fate of Smad2 in fibroblasts cultured in the presence of TGF-β or bortezomib or both. As expected, TGF-β triggered a pronounced phosphorylation of Smad2 in dermal fibroblasts. This phosphorylation was strong at 45 minutes and then decreased, although it remained detectable after 12 hours (Figure 3a). Bortezomib did not induce Smad2 phosphorylation on its own and did not modify Smad2 phosphorylation induced by TGF-β (Figure 3a). Bortezomib was active, however, since c-Jun phosphorylation was induced as expected [21] at late time points (Figure 3a).

Upon phosphorylation, Smad2 is known to translocate into the nucleus in response to TGF-β [34]. Pre-incubation of fibroblasts with bortezomib did not alter the cytoplasmatic pattern of Smad2 in resting fibroblasts or its nearly complete nuclear translocation at 1 hour after the addition of TGF-β (Figure 3b). Furthermore, bortezomib did not alter the exclusive nuclear localization of p300, regardless of the presence or absence of TGF-β (Figure
3b). Finally, using a synthetic biotinylated probe (sequence in Table 1) in a pull-down assay, we quantified binding of phospho-Smad2 to the SP1 sequence of the COL1A2 promoter. In these experiments, TGF-β induced a substantial increase in binding of phospho-Smad2. The simultaneous presence of bortezomib did not reduce but instead enhanced binding of phospho-Smad2 in response to TGF-β, while bortezomib on its own did not induce any binding (Figure 3c). Taken together, these findings demonstrate that PI does not alter TGF-β-induced Smad2 phosphorylation, nuclear translocation, or binding to the COL1A2 promoter. Impaired Smad2 activation thus cannot explain the reduced production of collagen when fibroblasts are stimulated by TGF-β in the presence of PI.

Differential effects of proteasome inhibition and TGF-β on MMP-1 and MMP-2

MMPs play a major role in ECM degradation and are differentially regulated by TGF-β, which was reported to decrease MMP-1 and increase MMP-2 production by fibroblasts [16,18]. We were therefore interested in investigating the effect of PI on MMP production in the presence or absence of TGF-β. We confirmed that bortezomib stimulated MMP-1 production and that this increase was dominant over the inhibitory effect of TGF-
β, both at the mRNA and protein levels (Figure 4a, c) [21]. Furthermore, bortezomib modestly decreased basal and TGF-β induced MMP-2 mRNA expression (Figure 4b).

Thus, PI differentially affects the regulation of MMP-1 and MMP-2 production in fibroblasts. It should be emphasized that the MMP-1 mRNA half-life in the presence of the transcriptional inhibitor 5,6-dichlorobenzimidazole riboside (DRB) with and without proteasome inhibitor exceeded 24 hours (data not shown). However, steady-state MMP-1 mRNA levels increased in the presence of PI (Figure 4a). It is thus highly unlikely that MMP-1 mRNA stability is significantly affected by PI.

Proteasome inhibition activates the MMP-1 promoter by inducing binding of c-Jun to the proximal AP-1 site

To identify the promoter sequences that are necessary and sufficient for driving the induction of MMP-1 in response to PI, we assessed the impact of bortezomib on fibroblasts transiently transfected with reporter gene constructs carrying either an intact MMP-1 promoter or a mutated MMP-1 promoter in which a binding site for c-Jun/c-Fos was replaced by a c-Jun/ATF-2 binding site (Figure 5a and Table 1) [31]. In the presence of bortezomib, a 5.1-fold increase in activity of the intact MMP-1 promoter was observed at 4 hours (Figure 5b). This increase was similar in magnitude to that observed in cells treated with TNF-α (3.9-fold), which was used as a positive control. Interestingly, the increase in MMP-1 promoter activity was long-lasting and remained high after 24 hours of culture (Figure 5b). Mutation of the AP-1 site in the promoter resulted in a substantial reduction in MMP-1 induction by bortezomib (2.2-fold at 4 and 24 hours) and unresponsiveness to TNF-α (0.9-fold) (Figure 5b). This demonstrates that optimal bortezomib-induced activation of MMP-1 transcription requires an AP-1 binding site recognized preferentially by a c-Jun/c-Fos heterodimer.
To confirm the involvement of c-Jun in bortezomib-mediated induction of MMP-1 transcription, we assessed its in vivo binding to the promoter region of the MMP-1 gene by ChIP. We focused on the promoter proximal region on the basis of published regulatory sites in the MMP-1 promoter (Figure 5a) [35] and the results we obtained using the mutated MMP-1 promoter. Bortezomib provoked a strong increase in binding of c-Jun to the promoter region, comparable to that induced by TNF-α (3.7- versus 5.2-fold) (Figure 5c). Enhanced binding of c-Jun to the MMP-1 promoter was specific as the AP2 transcription factor did not exhibit an increase in binding upon either treatment, and binding of c-Jun to the MMP-2 or MMP-9 promoters was not enhanced (Figure 5c). Thus, the differential effect of bortezomib on MMP-1 and MMP-2 expression is dependent, at least in part, on the specific characteristics of their promoter regions.

The MMP-1 promoter contains at least two proximal AP-1 binding sites, separated by less than 100 nucleotides. Based on the literature, we postulated that the most proximal site was likely to be the bortezomib-responsive element. We therefore performed electrophoretic mobility shift assays (EMSAs) with double-stranded oligonucleotides corresponding to the most proximal AP-1 site of the MMP-1 promoter (Table 1 for oligonucleotide sequences). Incubation of the MMP-1 probe with nuclear extracts from untreated fibroblasts (Figure 5d, left panel) led to the formation of two protein-DNA complexes, of which only the upper band was modulated by treatment (gray arrow), demonstrating the binding of one or several transcription factors to this synthetic DNA sequence. Competition with cold oligonucleotides dem-
onstrated the specificity of this binding. The presence of c-Jun among the bound proteins was indicated by the appearance of a supershifted band (white arrow) upon pre-incubation with anti-c-Jun antibodies. No supershift was observed in the presence of control anti-Ets-1 antibodies (Figure 5d, middle panel). Similar patterns were obtained with nuclear extracts generated from bortezomib- and TNF-α-treated fibroblasts (Figure 5d, right panel). Finally, DNA pull-down experiments revealed a marked increase in the amount of c-Jun bound to the biotinylated MMP-1 probe upon bortezomib treatment (Figure 5e). Taken together, these experiments demonstrate that PI results in a specific increase in binding of c-Jun to the most proximal AP-1 site of the MMP-1 promoter. We next investigated whether binding of c-Jun to the MMP-1 promoter in the presence of bortezomib was regulated by TGF-β. This was not the case since ChIP experiments revealed that bortezomib-induced binding of c-Jun to the MMP-1 promoter was not affected by TGF-β (Figure 6a). Of note, under the same culture conditions, TGF-β-induced binding of SP1 to the promoter region of COL1A2 was abrogated by bortezomib (Figure 6b). In control experiments, binding of c-Jun did not increase at the COL1A2 promoter, nor did binding of SP1 at the MMP-1 promoter (data not shown). Furthermore, the specificity of our ChIP assays was emphasized by the fact that no binding of c-Jun or SP1 was observed within the open reading frames (ORFs) of the MMP-1 or COL1A2 genes (Figure 6a, b). In conclusion, the effect of PI dominates the influence of TGF-β in controlling the binding of both SP1 to COL1A2 and c-Jun to MMP-1.

Discussion

The major finding of our work is that the overall antifibrotic activity of PI by bortezomib results from two distinct but functionally converging regulatory effects summarized in Figure 7. On one hand, we have documented that enhanced transcription of the MMP-1 gene depends on enhanced binding of c-Jun to the most proximal AP-1 site of the MMP-1 promoter. On the other hand, we have shown that inhibition of SP1 binding to the promoter of COL1A2 correlates with decreased COL1A2 transcription in both unstimulated and TGF-β-stimulated fibroblasts. It is noteworthy that these promoter elements were previously shown to be important for regulating the transcription of MMP-1 [35] and COL1A2 [9,36], respectively.

The stimulatory effect we observed on MMP-1 expression was specific to this particular MMP since bortezomib decreased MMP-2 transcription. This could be explained by the absence of AP-1 binding sites in the MMP-2 promoter (Figure 5a). However, the MMP-1 pro-
moter shares highly conserved consensus AP-1 binding sequences with other MMP promoters, including MMP-9 (Figure 5a), which may suggest that the activation by bortezomib is not restricted to MMP-1. While we have not directly assessed whether MMP-9 transcription was enhanced by PI, we did not observe enhanced binding of c-Jun to the AP-1 site in the promoter of MMP-9. This may be due to the influence of sequences adjacent to the AP-1 site or to the composition of the AP-1 complex that binds there, and this complex could correspond to c-Jun homodimers or heterodimers of c-Jun with JunB, JunD, or c-Fos. In particular, a notable difference is the presence of an Ets-1 site next to the distal AP-1 site (-1604) in MMP-1 but not in MMP-9. In agreement with previous observations [37], we postulate that the presence of an Ets-1 site next to an AP-1 sequence enhances the binding of c-Jun to the AP-1 site, thereby increasing transcription of the downstream gene. This is consistent with the finding that bortezomib-induced MMP-1 transcription is reduced in reporter gene assays when the Ets-1 site in the MMP-1 promoter is mutated.

Our investigation of the effect of bortezomib on type I collagen synthesis revealed that reduced COL1A2 transcription correlated with decreased binding of SP1 to the COL1A2 promoter. This was observed under both basal and TGF-β-induced conditions. Since we previously demonstrated that PI did not affect COL1A1 mRNA stability [21], decreased transcription explains the PI effect. SP1 is known to be a crucial cis-acting element for basal COL1A2 transcription and also to play an important role in mediating TGF-β-induced transcription [8,38]. Furthermore, hyper-phosphorylation of SP1 is characteristic...
Figure 6 Bortezomib and TGF-β exert opposing regulation on COL1A and MMP-1 genes. Fibroblasts were treated with TGF-β (5 ng/mL) for 4 hours or bortezomib (1 μM) for 16 hours or both (TGF-β was added 1 hour after bortezomib) for 4 hours or were left untreated. Chromatin immunoprecipitations were performed with anti-c-Jun and anti-SP1 antibodies, and the results were quantified by real-time polymerase chain reaction using primers hybridizing the promoter (black bar) or the open reading frame (ORF) (white bar) region of either gene (Table 1). The increases in binding of c-Jun to the MMP-1 promoter (a) and of SP1 to the COL1A2 promoter (b) in treated cells relative to untreated cells are reported. Specificity of the experiments was controlled by assessing binding of c-Jun or SP1 to the ORF of the MMP-1 (a) and COL1A2 (b) genes, respectively. The data represent the mean ± standard deviation of three independent experiments; **P < 0.005 and ***P < 0.0005 in comparison with untreated cells. Bor, bortezomib; B/T, bortezomib/transforming growth factor-beta; COL1A, collagen 1A; MMP, matrix metalloproteinase; TGF-β, transforming growth factor-beta; UT, untreated.
of SSc dermal fibroblasts [39]. It is therefore likely that the effect of bortezomib on type I collagen synthesis is mediated, at least in part, by its capacity to reduce SP1 binding to the promoter of COL1A2. We were unable, however, to link decreased SP1 binding to upstream events. In particular, we tested the hypothesis that reduced SP1 binding might be associated with an effect of bortezomib on canonical Smad signaling in response to TGF-β. Indeed, recent studies on TGF-β signaling have revealed the ability of Smads to interact with various components of the 26S proteasome system [40]. Such interactions are now known to contribute to the regulation of Smad protein levels before and after Smad activation [41]. Most importantly, such interactions have also been shown to contribute to the signaling functions of Smads. This involves interactions with several proteins, such as Smad ubiquitination regulatory factors (Smurfs), the oncoprotein SnoN, and the multi-domain docking protein HEF1. Proteasomal degradation of these proteins links TGF-β signaling to multiple signaling pathways [42]. In our experimental conditions, however, bortezomib did not affect Smad2 phosphorylation or nuclear translocation and actually increased its binding to the COL1A2 promoter. In this context, it could be speculated that increased affinity of a single factor can have a negative effect on transcription, and this may explain the negative effect of bortezomib on COL1A2 synthesis. TGF-β-stimulated transcription of COL1A2 is triggered by binding of a large transcription factor complex, which is composed of Smad2/3, Smad4, SP1, and the transcription factor p300 [43]. In this complex, Smad2/3 has been reported to interact directly with both SP1 and p300 [44]. Although no direct interaction between SP1 and p300 has been reported at the COL1A2 promoter, a recent study demonstrated that SP1 binds p300 and recruits it for NECL1 transcription [45]. Since bortezomib did not prevent Smad2 binding to COL1A2, it can be hypothesized that it affects SP1 directly or perturbs in a more subtle manner the interactions of SP1 with Smad2/3 or p300. In this respect, it is interesting to note that p300/CBP sequestration by c-Jun or STAT1 has been proposed to explain, at least in part, the antagonism exerted on collagen synthesis by TNF-α and interferon-gamma, respectively [44,46,47]. Thus, c-Jun, which we have demonstrated to be increased in PI-treated fibroblasts [21], is known to participate in the functional availability of p300 [48,49]. In addition, PI has been shown to affect the histone acetyltransferase activity of p300 [50,51], which could affect binding of transcription factors to the COL1A2 promoter. Finally, off-DNA complexes formed by the increased availability of c-Jun with other specific or general transcription factors may be at play. In the present work, we have not directly assessed the effect of bortezomib on SSc fibroblasts. However, in terms of type I col-

![Figure 7 Bortezomib overrides the effect of TGF-β and imposes its anti-fibrotic activity](image-url)
lagent and MMP-1 protein production, SSc and control fibroblasts were previously found to behave similarly when submitted to PI [21].

Conclusions
By altering the binding of at least two transcription factors, c-Jun and SP1, PI results in increased production of MMP-1 and decreased synthesis of type I collagen in human dermal fibroblasts, thus providing a novel rationale for assessing the potential of drugs targeting the proteasome for their anti-fibrotic properties.

Abbreviations
AP-1: activation protein-1; CBP: CREB-binding protein; ChIP: chromatin immunoprecipitation; COL1A: collagen 1A; DTT: diithiothreitol; ECM: extracellular matrix; EDTA: ethylenediaminetetraacetic acid; EMSA: electrophoretic mobility shift assay; FCS: fetal calf serum; MMP: matrix metalloproteinase; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PI: proteasome inhibition; PMSF: phenylmethylsulfonyl fluoride; SSc: systemic sclerosis; TGF-B: transforming growth factor-beta; TIMP: tissue inhibitor of matrix metalloproteinase; TNF-a: tumor necrosis factor-alpha.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
LG conceived experiments, performed research, analyzed the data, and drafted the manuscript. QS-E conceived experiments and performed research. MA performed research. LG conceived experiments, performed research, analyzed the data, and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported in part by grant 31003A_124941/1 from the Swiss National Science Foundation and the E. Boninchi Foundation (to CC).

Author Details
1. Immunology and Allergy, Department of Internal Medicine, Geneva University Hospital and School of Medicine, rue Gabrielle Perret-Gentil 4, 1211 Geneva 14, Switzerland and 2. Department of Pathology and Immunology, Geneva University Hospital and School of Medicine, rue Michel Servet 1, 1211 Geneva 14, Switzerland

Received: 10 December 2009 Revised: 1 April 2010 Accepted: 29 April 2010 Published: 29 April 2010

References
1. Varga JA, Trojanowska M: Fibrosis in systemic sclerosis. Rheum Dis Clin North Am 2008, 34:115-143. vii
2. Ihn H: Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 2005, 7:156-162.
3. Gabrielli A, Avvedimento EV, Krieg T: A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-beta. Cell 1988, 52:405-414.
4. Inagaki Y, Truter S, Ramirez F: Transforming growth factor-beta stimulates alpha 2(I) collagen gene expression through a cis-acting element that contains a Sp1-binding site. J Biol Chem 1994, 269:14828-14834.
5. Varga JA, Trojanowska M: Transforming growth factor-beta and autoimmune diseases. Curr Opin Drug Discov Devel 2008, 11:361-369.
6. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Vincenti R, Fumagalli M, Viale G: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
7. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
8. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
9. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
10. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
11. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
12. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
13. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
14. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
15. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
16. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
17. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
18. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
19. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
20. Fineschi S, Rech T, Guerri G, Parini L, Zazzali U, Porta A, Pizzorni C, Mancini M, Viale G, Vincenti R, Fumagalli M: Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. J Clin Invest 2006, 116:229-241.
27. Fineschi S, Bongiovanni M, Donati Y, Djaafar S, Naso F, Goffin L, Barazzone Angirocco C, Pache J-C, Dayer J-M, Ferrari-Lacraz S, Chozollini C. *In vivo* investigations on anti-fibrotic potentials of proteasome inhibition in lung and skin fibrosis. *Am J Respir Cell Mol Biol* 2008, 39:458-465.

28. Sinha R, Kaufman J, Lonial S. Novel treatment approaches for patients with multiple myeloma. *Clin Lymphoma Myeloma* 2006, 6:281-288.

29. Kaufman J, Lonial S. Proteasome inhibition: novel therapy for multiple myeloma. *Onkologie* 2006, 29:162-168.

30. Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K, Sezer O. Proteasome: an emerging target for cancer therapy. *Anticancer Drugs* 2005, 16:475-481.

31. van Dam H, Duyndam M, Rottier R, Boshch A, de Vries-Smits L, Herrlich P, Masternak K, Peyraud N, Krawczyk M, Barras E, Reith W, Kypriotou M, Beauchef G, Chadjichristos C, Widom R, Renard E, Jimenez J, Maquart F-X, Oddos T, Von Stetten O, Pujol J-P, Galera P. Human collagen Krox up-regulates type I collagen expression in normal and scleroderma fibroblasts through interaction with Sp1 and ATF-2 is responsible for induction of c-Jun by the 243 amino acid adenovirus E1A protein. *EMBO J* 1993, 12:479-487.

32. Kypriotou M, Beauchef G, Chadjichristos C, Widom R, Renard E, Jimenez SA, Korn J, Maquart F-X, Oddos T, Von Stetten O, Pujol J-P, Galera P. Human collagen Krox up-regulates type I collagen expression in normal and scleroderma fibroblasts through interaction with Sp1 and Sp3 transcription factors. *J Biol Chem* 2007, 282:32000-32014.

33. Masternak K, Peyraud N, Krawczyk M, Barras E, Reith W. Chromatin remodeling and extragenic transcription at the MHC class II locus control region. *Nat Immunol* 2003, 4:132-137.

34. Derynck R, Zhang YE. Regulation of matrix metalloproteinase gene expression. *J Cell Physiol* 2007, 211:19-26.

35. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. *J Cell Physiol* 2007, 211:19-26.

36. Ramirez F, Tanaka S, Bou-Gharios G. Transcriptional regulation of the human alpha 2(I) collagen gene (COL1A2), an informative model system to study fibrotic diseases. *Matrix Biol* 2006, 25:365-372.

37. Gutman A, Wasylky B. The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. *EMBO J* 1990, 9:2241-2246.

38. Tamaki T, Ohnishi K, Hartl C, LeRoy EC, Trojanowska M. Characterization of a Gc-rich region containing Sp1 binding site(s) as a constitutive response element of the alpha 2(I) collagen gene in human fibroblasts. *J Biol Chem* 1995, 270:4299-4304.

39. Ihn H, Tamaki K. Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. *Arthritis Rheum* 2000, 43:2240-2247.

40. Zhang F, Laiho M. On and off: proteasome and TGF-beta signaling. *Exp Cell Res* 2003, 291:278-281.

41. Lo RS, Massague J. Ubiquitin-dependent degradation of TGF-beta-activated smad2. *Nat Cell Biol* 1999, 1:472-478.

42. Sato M, Shogogut D, Gore EA, Smith EA, McDermott Pj, Trojanowska M. Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. *Invest Dermatol* 2002, 118:704-711.

43. Ghosh A, Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. *Rheumatology* 2006, 45:157-165.

44. Gao J, Chen T, Liu J, Liu W, Hu G, Guo X, Yin B, Gong Y, Zhao J, Qiang B, Yuan J, Peng X. Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site. *Glia* 2009, 57:989-999.

45. Verrecchia F, Pessah M, Atfi A, Mauviel A. Tumor necrosis factor-alpha inhibits transforming growth factor-beta/Smad signaling in human dermal fibroblasts via AP-1 activation. *J Biol Chem* 2000, 275:30226-30231.

46. Ghosh AK, Yuan W, Mori Y, Chen S, Varga J. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CREB transcriptional coactivators. *J Biol Chem* 2001, 276:11041-11048.

47. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. *Blood* 2008, 111:3131-3136.

48. Shin DH, Li SH, Chun YS, Huang LE, Kim MS, Park JW. CITED2 mediates the paradoxical responses of HIF-1alpha to proteasome inhibition. *Oncogene* 2008, 27:1939-1944.

49. Marcu MG, Jung YJ, Lee S, Chung EJ, Lee MJ, Trepel J, Neckers L. Curcumin is an inhibitor of p300 histone acetyltransferase. *Med Chem* 2006, 2:169-174.

50. Sanchez-Molina S, Oliva JL, Garcia-Vargas S, Valls E, Rojas JM, Martinez-Balbas MA. The histone acetyltransferases CBP/p300 are degraded in NIH 3T3 cells by activation of Ras signalling pathway. *Biochem J* 2006, 398:215-224.